Group 1 - HII's Newport News Shipbuilding division will host commencement exercises for the class of 2025 graduates from the Newport News Shipbuilding Apprentice School, with U.S. Secretary Linda McMahon providing the commencement address [1][3] - The Newport News Shipbuilding Apprentice School accepts over 200 apprentices annually, offering four- to eight-year, tuition-free apprenticeships in 19 trades and six optional programs, and is accredited to offer associate degrees in applied science in maritime technology [1][2] - HII is America's largest shipbuilder, specializing in delivering powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers [2][3] Group 2 - HII has a workforce of 44,000 and has a history of over 140 years in advancing U.S. national security, building and integrating defense capabilities from core fleet to advanced technologies [3] - The graduation ceremony will take place at Liberty Live Church in Hampton, Virginia, on March 21 at 10 a.m., and will be livestreamed for public viewing [1][3]

Core Insights - HII's Ingalls Shipbuilding division celebrated the graduation of 70 apprentices, highlighting the importance of skilled craftsmen in the shipbuilding industry [1][2] - The Ingalls Apprentice School has graduated over 4,000 shipbuilders since its inception in 1952 and currently supports more than 750 students [2][5] - The program offers specialized training in 15 U.S. Department of Labor-registered trades, providing apprentices with competitive wages and benefits [2] Group 1 - The Ingalls Apprentice School is recognized as the backbone of Ingalls' workforce, with many graduates advancing to leadership roles [5] - This year's Overall Apprentice of the Year was joiner apprentice Sawyer Briggs, who emphasized the program's role in preparing him for a successful career [4][5] - Ingalls Shipbuilding has been a key player in designing, building, and maintaining amphibious ships and destroyers for the U.S. Navy for over 87 years [5] Group 2 - HII is America's largest shipbuilder, delivering advanced ships and mission technologies to U.S. and allied defense customers [7] - The company has a workforce of 44,000 and has a history of over 140 years in advancing U.S. national security [8] - HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world [7]

March 2026 NASDAQ: ATLC Investor Presentation Forward-Looking Statements This presentation contains forward-looking statements that are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements, among other things, concerning the benefits of the acquisition of Mercury Financial, including expected synergies, cost savings and enhanced capabilities; the optimization of the acquired Mercury Financial portfolio; our busin ...

Core Insights - Compugen Ltd. reported significant progress in 2025, including a non-dilutive monetization agreement with AstraZeneca that extends its cash runway into 2029, enhancing its financial stability and preserving the potential value of its assets [2][4]. Financial Highlights - As of December 31, 2025, Compugen had approximately $145.6 million in cash and equivalents, bolstered by a $65 million upfront payment from AstraZeneca for royalty monetization [3][4]. - Revenues for Q4 2025 were approximately $67.3 million, and for the full year, revenues reached approximately $72.8 million, a significant increase from $27.9 million in 2024 [4][6]. - The company reported a net profit of approximately $56.8 million for Q4 2025, translating to about $0.60 per share, compared to a net loss of approximately $6.1 million in Q4 2024 [10][15]. Clinical Development and Pipeline - Compugen initiated new clinical trials for COM701 (MAIA-ovarian) and GS-0321 in 2025, expanding its clinical footprint across the U.S., Israel, and France [2][4]. - The company is on track for an interim analysis of the MAIA-ovarian trial in Q1 2027, with promising data presented at ESMO 2025 [4][10]. - Compugen continues to invest in early-stage discovery programs targeting undisclosed drug candidates, leveraging its AI/ML-powered computational discovery platform [2][12]. Strategic Partnerships - The partnership with AstraZeneca includes potential milestone payments of up to $1 billion, in addition to future royalties, which positions Compugen for long-term financial success [2][4][5]. - Gilead is collaborating with Compugen on the GS-0321 program, further diversifying the company's pipeline and revenue potential [2][12].

Core Insights - Supermicro has launched the industry's first and highest-density blade server platform powered by AMD EPYC 4005 series processors, optimized for cloud, edge, and SaaS workloads [1] - The new MicroBlade platform supports up to 40 server nodes in a 6U enclosure, providing unmatched scalability, flexibility, and energy efficiency [1] - The system is designed for various specialized compute applications, including e-commerce, cybersecurity, and data services, enhancing its versatility for different workloads [1] Product Features - The MicroBlade system can incorporate up to 320 server nodes in a standard 48U rack, allowing for flexible configurations with different CPU types [1] - Each node supports a single AMD EPYC 4005 series processor, two DDR5 ECC UDIMM slots, and multiple SSD options, ensuring high performance and efficiency [1] - Integrated networking features include dual-port 25GbE and advanced security measures such as TPM 2.0 and hardware root of trust [1] Management and Control - The MicroBlade chassis management module (CMM) allows for total remote control of server blades, power supplies, and networking switches, enhancing operational efficiency [1] - System administrators can manage power consumption and perform remote reboots or resets, ensuring optimal performance and uptime [1] - The separate controller for monitoring and control functions operates independently of CPU status, ensuring reliability [1] Company Overview - Supermicro is a global leader in Application-Optimized Total IT Solutions, focusing on innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure [1] - The company designs and manufactures its products in-house, leveraging global operations to optimize total cost of ownership and reduce environmental impact [1] - Supermicro's award-winning portfolio includes a broad family of systems built from flexible and reusable building blocks, catering to various workloads and applications [1]

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that utilizes AI/ML for drug target discovery [1] - The company will participate in two upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Partners 2026 Global Healthcare Conference [1] Company Overview - Compugen is focused on developing cancer immunotherapies through its AI/ML powered computational discovery platform, Unigen™ [1] - The company has two main programs targeting TIGIT: COM902, a fully owned anti-TIGIT antibody in Phase 1, and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca [1] - Additional programs include COM701, a potential first-in-class anti-PVRIG antibody, and GS-0321, a high affinity anti-IL-18 binding protein antibody licensed to Gilead [1] Upcoming Events - The Oppenheimer conference will take place on February 26, 2026, featuring a fireside chat at 2 PM ET [1] - The Leerink Partners conference is scheduled for March 9, 2026, with a fireside chat at 8:40 AM ET [1] - Live webcasts of the fireside chats will be available on Compugen's Investor Relations website [1]

Core Insights - Arista Networks, Inc. (ANET) reported strong fourth-quarter 2025 results, with revenues and adjusted earnings significantly increasing year over year, driven by robust demand trends and innovative product launches [1] Financial Performance - GAAP net income for the quarter rose to $955.8 million or 75 cents per share, up from $801 million or 62 cents per share in the previous year [2] - Non-GAAP net income reached a record high of $1.05 billion or 82 cents per share, compared to $849.6 million or 66 cents per share in the year-ago quarter, beating the Zacks Consensus Estimate by 7 cents [2] - For the full year 2025, GAAP earnings were $3.51 billion or $2.75 per share, an increase from $2.85 billion or $2.23 per share in 2024 [3] Revenue Growth - Quarterly revenues surged to $2.49 billion from $1.93 billion in the prior-year quarter, exceeding the consensus estimate of $2.37 billion [4] - Total revenues for 2025 increased to $9.01 billion from $7 billion in 2024, driven by strong demand across the product portfolio [4] Product and Service Performance - Net quarterly sales from products totaled $2.09 billion, up from $1.61 billion in the year-ago quarter, while service revenues increased to $392.1 million from $322.3 million [5] - The Americas contributed approximately 79% to total revenues, with international revenues making up the remainder [6] Profitability Metrics - Non-GAAP gross profit rose to $1.58 billion with respective margins of 63.4% and 64.2%, although the margin declined year over year due to a higher mix of sales to cloud and AI Titan customers [7] - Total operating expenses increased to $530.9 million from $431.4 million in the year-ago quarter, but operating income rose to $1.03 billion from $799.6 million [8] Future Outlook - For Q1 2026, management expects revenues to be approximately $2.6 billion, with a projected 25% revenue growth for 2026 [9][11] - Non-GAAP gross margin is expected to be between 62-63% and non-GAAP operating margin around 46% for Q1 2026 [11] Cash Flow and Liquidity - In 2025, Arista generated $4.37 billion of net cash from operating activities, compared to $3.71 billion in 2024 [10] - As of December 31, 2025, the company had $1.96 billion in cash and cash equivalents [10]

Core Viewpoint - Zealand Pharma A/S will host a conference call on February 19, 2026, to present its full year 2025 financial results [1] Group 1: Conference Call Details - The call will feature President and CEO Adam Steensberg, CFO Henriette Wennicke, and CMO David Kendall, followed by a Q&A session [2] - A live audio webcast and accompanying slide presentation will be available online [3] - Participants are encouraged to register approximately 10 minutes before the call, and a recording will be accessible on the company's website afterward [4] Group 2: Company Overview - Zealand Pharma A/S is focused on developing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise and advanced data-driven approaches [5] - The company has over ten drug candidates in clinical development, with two products already on the market and three in late-stage development [6] - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in Boston, Massachusetts [6]

Core Viewpoint - Compugen has appointed Michele Holcomb, Ph.D., as an independent director to its Board of Directors, effective February 11, 2026, bringing over 30 years of experience in biotech, pharmaceuticals, and healthcare services [1] Group 1: Appointment Details - Michele Holcomb's extensive background includes strategic insights, corporate development, and operational experience, which will enhance Compugen's Board [1] - The appointment is expected to strengthen the company's ability to convert clinical opportunities into long-term value for patients and shareholders [1] Group 2: Company Overview - Compugen is a clinical-stage cancer immunotherapy company utilizing AI/ML for drug target discovery [1] - The company has multiple first-in-class clinical programs and partnerships, including two validating pharma partnerships [1] - Compugen's pipeline includes several differentiated programs targeting TIGIT and other novel drug targets [1] Group 3: Dr. Holcomb's Background - Dr. Holcomb has held significant roles, including EVP at Cardinal Health and COO at Teva Pharmaceuticals, focusing on strategy and business development [1] - She has experience in managing partnerships, acquisitions, and optimizing portfolios in the healthcare sector [1] - Dr. Holcomb serves on various boards and has a strong academic background with a BS and PhD in chemistry [1]

Powering Our Critical Energy Future February 5, 2026 Disclaimer Cautionary Note Regarding Forward-Looking Statements. This presentation contains "forward-looking statements" and information based on the current beliefs of Kodiak Gas Services, Inc. (the "Company"). Forward- looking statements in this communication are identifiable by the use of the following words, the negative of such words, and other similar words: "anticipates," "assumes," "believes," "could," "estimates," "expects," "forecasts," "goal," ...